Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial - Wikidata - wikimedia - TriplyDB

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial

http://www.wikidata.org/entity/Q37712223

about

Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis Bisphosphonates and other bone agents for breast cancer Bisphosphonates in breast cancer Heel ultrasound can assess maintenance of bone mass in women with breast cancer.Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.Medication-induced osteoporosis: screening and treatment strategies Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor.Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline Osteoporosis and aromatase inhibitors: experience and future prospects Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy.Skeletal manifestations of treatment of breast cancer.A retrospective study on screening and management of osteoporosis in breast cancer women treated with aromatase inhibitors in Libya.Emerging drugs for the management of cancer treatment induced bone loss.Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG The use of bisphosphonates in cancer treatment.Aging and osteoporosis in breast and prostate cancer.The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer.Optimal management of cancer treatment-induced bone loss: considerations for elderly patients.A review of osteoporosis management in younger premenopausal women.Adjuvant Endocrine Therapy and Bone Health in Breast Cancer.Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole.Bisphosphonates and other bone agents for breast cancer.Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience.Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.

P2860

Q21132670-53035047-7B8C-4E09-8922-843E9E3DD11E Q24203656-1FDFB060-1AA7-4CCA-BFC9-97C8D5686CEC Q26859326-B980EC52-6592-472F-BA73-FDF9C9FDFDBC Q30383587-0BBE3316-0F33-482A-93E9-CC507C2B7FEB Q30416847-08D08497-FA34-4E03-A3BA-758A9F24E6C7 Q33802932-22F50674-6106-4CA6-B247-E42A018026B3 Q34389358-669DB9C1-78DB-4D11-8EF9-1FE107DEC150 Q34680563-99AC3BFF-7F25-4E2A-AF57-21F933EBB02A Q35012609-3C095506-C029-4B1A-8AEF-0661334300CE Q35076216-3C9ECE2B-AB0A-4FD5-AF85-2C296D926E05 Q35095538-2B65E2B6-02A7-4801-9152-CAE329B3FFB1 Q35194455-C14BE18C-5EB3-4A1E-9F2A-BF4D9D2C331D Q35583788-924840F3-4F94-4F71-9342-B90FA3976A12 Q35750472-7D6E37D5-F5D8-4745-B565-CC344CF8FDF1 Q36333474-29941590-E184-4472-8310-F23AE6E8637F Q36616992-45D0D676-D23B-4FFA-AF4A-86E070731425 Q37350988-8D1FA984-0A1A-4039-8FB2-41D9A28F8420 Q37630298-58BB8F8B-3C00-4639-977F-1A50FF599179 Q37653246-392F7329-7DC3-4416-B49A-45B5E31B292A Q37727235-015FDD93-BBC3-4C28-BE39-92920F282F5D Q37742180-702BF1CE-C23C-434C-819A-F011D33C08A1 Q37800183-5762F74B-5807-4172-9E8F-D6E930392204 Q37872146-F86F9994-B871-44CE-81FB-BBE5DB7019B6 Q37944154-C7B7E03D-5535-4DA3-998A-298E593EFC53 Q37952851-E3C52B8A-D8F1-4F2A-898B-DA366BBA2728 Q38170408-998F9C00-8C50-406E-BD56-82E61BB98939 Q38553766-128CCDCB-EC83-4EA4-A272-4DF47FDF274D Q41684442-56C07BFF-0DD4-407B-86AA-35B7E965D5AF Q47693752-75B742E3-FEC2-4236-B529-5AA2EF21AA7E Q49344279-629A12E5-035A-4755-9B02-76395837928F Q53136867-4E78DC26-8DC4-4149-BD08-A131A07EBC2B

P2860

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial

http://www.wikidata.org/entity/Q37712223

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 April 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Risedronate prevents bone loss ...... cebo-controlled clinical trial

@en

Risedronate prevents bone loss ...... ebo-controlled clinical trial.

@nl

type

label

Risedronate prevents bone loss ...... cebo-controlled clinical trial

@en

Risedronate prevents bone loss ...... ebo-controlled clinical trial.

@nl

prefLabel

Risedronate prevents bone loss ...... cebo-controlled clinical trial

@en

Risedronate prevents bone loss ...... ebo-controlled clinical trial.

@nl

P1433

Q37712223-1A760D30-634B-4908-A1A9-D1508E70A008

P1476

Q37712223-B36321C1-FBC5-4FDF-B30F-B50EAD1C7618

P2093

Q37712223-24C30787-3556-438E-865F-5B5749689881

Q37712223-28EABBF5-2337-4A8C-B1D6-A73070CF27BD

Q37712223-4A19C07E-CE50-4891-8B1A-5E763AF04336

Q37712223-4BD9811E-332A-42CF-802A-7FE5C975B7CF

Q37712223-7BC2C1A3-5E6A-4E16-87C1-6B6FC210B9BB

Q37712223-8A67CF50-628F-48ED-AC4D-5375B3BA0437

Q37712223-AF166CBD-AE38-4896-B3EB-50E14AED6D52

Q37712223-CF99931D-9358-4CB1-B595-4E52694F4C57

P2860

Q37712223-15E0FE33-E8CF-4793-8133-FD66FA70CCD2

Q37712223-22E460E5-DAE2-47C2-98D1-03B1941E6089

Q37712223-2C0F715E-73C0-4A53-A1BE-20B3EC4FE1A5

Q37712223-32A50554-683F-4C2A-AD2B-66464EA92255

Q37712223-36033A09-7BD6-47CA-8FC0-CDCF08E132BD

Q37712223-3B9F32B1-4CB1-4F87-9E68-D43EFF6F0B28

Q37712223-42177542-00D3-4D56-8802-9F310B609AFA

Q37712223-465601B6-8AD0-45A4-A344-ABFC595D1917

Q37712223-62424268-DC47-4DFC-B7F7-4BD8ABA0C612

Q37712223-899EB68A-4D47-4684-9CEF-2258B97D54C2

P304

Q37712223-A20BC86D-0E44-4605-AE77-64AA6D44851B

P31

Q37712223-E5BD5D3E-1552-433F-9073-74B61AD88721

P356

Q37712223-77A380CA-B234-40F3-AD74-DD66C841E0BF

P407

Q37712223-2700E4D9-C892-4240-A57A-6FC0331EB428

P433

Q37712223-BDA3C23C-B8D4-48F5-AB3C-3690C3951E59

P478

Q37712223-A2139FD8-E2FA-4C41-B0C8-AE3BDCB96C02

P577

Q37712223-E9FFE62A-BD2A-4BE5-A78A-D78A4A9E6199

P5875

Q37712223-1B332EBD-A7E6-4EE2-AB40-7CE832D25696

P698

Q37712223-C846BCDE-9BE1-4808-9766-99E7CD1CC833

P921

Q37712223-762EC6AD-D022-41DA-AC1B-EBD9FD35FFB7

P932

Q37712223-366DC01F-E576-4B58-88FF-0BB978222054

P356

JCO.2007.15.2967

P1433

Journal of Clinical Oncology

P1476

Risedronate prevents bone loss ...... cebo-controlled clinical trial

@en

P2093

Adam Brufsky

http://www.w3.org/2001/XMLSchema#string

Barry C Lembersky

http://www.w3.org/2001/XMLSchema#string

Karen T Vujevich

http://www.w3.org/2001/XMLSchema#string

Rajib Bhattacharya

http://www.w3.org/2001/XMLSchema#string

Subashan Perera

http://www.w3.org/2001/XMLSchema#string

Susan L Greenspan

http://www.w3.org/2001/XMLSchema#string

Susan M Sereika

http://www.w3.org/2001/XMLSchema#string

Victor G Vogel

http://www.w3.org/2001/XMLSchema#string

P2860

Skeletal integrity in patients with nail patella syndrome

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

Osteoporosis due to cancer treatment: pathogenesis and management.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group.

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.

Aromatase inhibitors and bone loss.

Aromatase inhibitors and bone health in women with breast cancer.

P304

2644-2652

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.15.2967

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5426041

http://www.w3.org/2001/XMLSchema#string

P698

18427147

http://www.w3.org/2001/XMLSchema#string

P921

P932

3992822

http://www.w3.org/2001/XMLSchema#string